Tildrakizumab

• Evaluation of Tildrakizumab in the Treatment of Ocular Sequelae in Lyell syndrome Pending
  2025-522556-10-01 Phase II 1 country TOXILYON
• Tildrakizumab, an Anti-IL-23 Antibody for the Treatment of Refractory Chronic Spontaneous Urticaria – a single-arm, open-label, phase II stu… Recruiting
  2024-513155-32-00 Phase II 1 country Philipps-Universitaet Marburg
• Phase 3 study to evaluate the efficacy and safety of subcutaneous tildrakizumab in subjects with moderate to severe genital psoriasis. Ended
  2024-515672-12-00 Phase III 3 countries Sun Pharmaceutical Industries Limited
• An Open-Label Extension Study to Evaluate Long Term Safety and Efficacy of Tildrakizumab in Patients with Psoriatic Arthritis. Ended
  2022-501480-41-00 Phase III 7 countries Sun Pharmaceutical Industries Limited
• Study to see how good and safe Tildrakizumab is in children aged 6 to under 18 years of age with skin patches Ended
  2023-504447-14-00 Phase II/III 4 countries Sun Pharmaceutical Industries Limited
• A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Tildrakizumab in Anti-TNF Naive Su… Ended
  2024-512142-42-00 Phase III 4 countries Iqvia Biotech Limited; Labcorp Central Laboratory Services SARL; Sun Pharmaceuti…
• A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Tildrakizumab in Anti-TNF Experien… Ended
  2023-507415-35-00 Phase III 7 countries Sun Pharmaceutical Industries Limited

Showing 1–7 of 7 trials